Lunai Bioworks Inc. LNAI
Last close
2.39
2026-09-04
Market cap
$86.7M
2026-03-31 share count
52-week range
1.21 - 13.28
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-1.08
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | $42.8K |
| Cost of revenue | — | — | — | — | — | — | — | — | — | $5.3K |
| Gross profit | — | — | — | — | — | — | — | — | — | $37.5K |
| R&D | $537.4K | $2.7M | $4.2M | $8.4M | $15.7M | $4.7M | $2.5M | $617.0K | $62.8K | $804.2K |
| SG&A | $17.9M | $24.6M | $15.3M | $14.3M | $7.6M | $7.1M | $8.4M | $3.9M | $933.8K | $1.2M |
| Total operating expenses | $189.0M | $81.6M | $38.6M | $116.1M | $23.4M | $11.9M | $11.0M | $5.3M | $2.4M | $2.2M |
| Operating income | -$189.0M | -$81.6M | -$38.6M | -$116.1M | -$23.4M | -$11.9M | -$11.0M | -$5.3M | -$2.4M | -$2.1M |
| Interest expense | $725.7K | $1.0M | $580.3K | $122.0K | $379.6K | $104.3K | $43 | $143.3K | — | $2.4K |
| Pre-tax income | -$178.0M | -$88.4M | -$39.7M | -$113.4M | -$26.8M | -$11.4M | -$18.0M | -$6.4M | -$2.2M | -$2.2M |
| Income tax | $1.5K | $0 | — | $34 | $125.3K | — | — | $111.7K | $64.9K | $462.8K |
| Net income | -$178.0M | -$88.4M | -$39.7M | -$113.4M | -$26.7M | -$11.4M | -$18.0M | -$6.3M | -$2.1M | -$1.7M |
| EPS, basic | -1.08 | -0.91 | -0.71 | -2.16 | — | — | — | — | — | — |
| EPS, diluted | -1.08 | -0.91 | -0.71 | -2.16 | -0.57 | -0.25 | -0.48 | -0.29 | -0.17 | -0.18 |
| Shares, diluted (wtd. avg.) | $165.1M | $97.5M | $56.3M | $52.5M | — | — | — | — | $12.3M | $9.5M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $92.7K | $220.5K | $1.9M | $9.2M | $20.7M | $8.7M | $12.3M | $15.6M | $3.9M | $23.4K |
| Total current assets | $1.0M | $2.0M | $2.6M | $9.6M | $20.9M | $8.9M | $12.5M | $15.8M | $4.2M | $732.5K |
| Property, plant and equipment | $367.8K | $482.1K | $509.0K | $586.5K | $719.4K | $778.1K | $687.5K | $27.4K | — | — |
| Goodwill | $6.0M | $159.3M | $11.6M | $11.6M | $11.6M | $11.6M | $11.6M | $11.6M | — | — |
| Other intangibles | $166.0K | $30.0K | $39.7K | $44.3K | $65.9K | $77.3K | $93.3K | $111.5K | $124.4K | $135.7K |
| Total assets | $8.2M | $163.1M | $58.3M | $84.6M | $189.6M | $178.1M | $179.9M | $182.5M | $4.5M | $870.8K |
| Total current liabilities | $29.2M | $30.3M | $11.0M | $6.5M | $1.9M | $1.3M | $1.1M | $873.7K | $3.0M | $1.5M |
| Long-term debt | — | — | — | — | — | — | — | — | — | $102.9K |
| Total liabilities | $29.6M | $31.2M | $11.8M | $12.0M | $14.9M | $11.8M | $6.8M | $23.8M | $3.0M | $1.5M |
| Retained earnings | -$510.5M | -$332.5M | -$244.0M | -$204.3M | -$90.9M | -$64.2M | -$52.8M | -$34.8M | -$28.4M | -$26.3M |
| Total equity | -$21.3M | $132.0M | $46.5M | $72.6M | $174.7M | $166.3M | $173.1M | $158.7M | $1.5M | -$637.4K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.9M | -$11.0M | -$11.8M | -$15.7M | -$20.6M | -$10.5M | -$8.5M | -$4.3M | -$1.2M | -$1.5M |
| Depreciation and amortisation | $129.1K | $121.9K | $113.5K | $123.6K | $123.5K | $108.6K | $71.7K | $18.5K | $14.5K | $27.4K |
| Stock-based compensation | $3.3M | $4.7M | $3.5M | $5.2M | $1.3M | $884.7K | $2.1M | $63.7K | — | — |
| Capital expenditure | — | $70.4K | $29.8K | $5.2K | $48.9K | $184.5K | $716.7K | $30.0K | — | — |
| Investing cash flow | -$500.0K | -$1.3M | -$29.8K | -$5.2K | -$48.9K | -$184.5K | -$716.7K | -$575.7K | -$196.1K | $1.1M |
| Financing cash flow | $8.4M | $10.5M | $4.5M | $4.3M | $32.6M | $7.2M | $6.0M | $16.7M | $5.5M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001731122-25-001316.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |